Liepnieks Juris J, Benson Merrill D
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5126, USA.
Amyloid. 2007 Dec;14(4):277-82. doi: 10.1080/13506120701614032.
It has been hypothesized that transthyretin (TTR) amyloidosis may progress after orthotopic liver transplantation (OLT) as a result of continued amyloid fibril synthesis and deposition from normal TTR. To test this hypothesis amyloid fibrils were isolated from cardiac tissues of three patients who died 1(1/2) to 5(1/2) years after OLT: two with Val30Met and one with Thr60Ala TTR. The ratio of variant to normal TTR in each case was determined and compared with the ratio of variant to normal in cardiac tissues from seven patients who died with TTR amyloidosis but who had not had liver transplantation. Tissues from patients with TTR amyloidosis without OLT included three with Val30Met, two with Thr60Ala, one with deltaVal122, and one with Val122Ile. All tissues from patients without OLT had greater amounts of variant TTR than normal TTR except for the Val122Ile in which the ratio was 50:50. The overall median variant to normal ratio was 60:40 with a range of 50-70% variant. In contrast, the mean percentage of variant TTR in the three tissues from patients after OLT was 25% (range 20-35). These data are consistent with the continued deposition of normal TTR in cardiac tissue after liver transplantation.
据推测,由于正常甲状腺素运载蛋白(TTR)持续合成并沉积淀粉样原纤维,甲状腺素运载蛋白淀粉样变性可能在原位肝移植(OLT)后进展。为验证这一推测,从3例OLT术后1.5至5.5年死亡患者的心脏组织中分离出淀粉样原纤维:2例为Val30Met型,1例为Thr60Ala型TTR。测定每种情况下变异型与正常型TTR的比例,并与7例死于TTR淀粉样变性但未接受肝移植患者心脏组织中的变异型与正常型比例进行比较。未接受OLT的TTR淀粉样变性患者的组织包括3例Val30Met型、2例Thr60Ala型、1例deltaVal122型和1例Val122Ile型。除Val122Ile型比例为50:50外,未接受OLT患者的所有组织中变异型TTR含量均高于正常型TTR。变异型与正常型的总体中位数比例为60:40,变异型范围为50 - 70%。相比之下,OLT术后患者的三个组织中变异型TTR的平均百分比为25%(范围20 - 35%)。这些数据与肝移植后心脏组织中正常TTR的持续沉积一致。